Prostate‐derived Ets transcription factor as a favorable prognostic marker in ovarian cancer patients
Open Access
- 19 June 2008
- journal article
- early detection-and-diagnosis
- Published by Wiley in International Journal of Cancer
- Vol. 123 (6), 1376-1384
- https://doi.org/10.1002/ijc.23667
Abstract
We have previously shown that ovarian tumors express prostate‐derived Ets transcription factor (PDEF). However, the precise role of PDEF in the prognosis of ovarian cancer is unknown. In our study, we report for the first time that expression of PDEF in tumor lesions of patients with ovarian cancer is associated with favorable prognosis. Evaluation of samples from 40 patients with ovarian cancer showed that early stage (IA) and borderline (IIB, III) ovarian tumors expressed higher levels of PDEF mRNA and protein and lower levels of survivin compared to late stage ovarian tumors (IIIC and IV, p < 0.05). Normal ovarian tissues expressed the highest levels of PDEF mRNA and protein when compared to tumor tissues (p < 0.05). A Log‐Rank test showed that overall survival of patients with PDEF‐positive and survivin‐negative ovarian tumors was significantly longer than those with PDEF‐negative and survivin‐positive tumors (p < 0.01). Forced expression of PDEF in PDEF‐negative ovarian tumor cells inhibited tumor cell growth, induced apoptosis, downregulated survivin expression and its promoter activity. Furthermore, treatment of ovarian cancer cells with vitamin D or a selenium compound resulted in re‐expression of PDEF, downregulation of survivin, induction of apoptosis and inhibition of tumor cell growth when compared to untreated controls (p < 0.05). Together, these observations showed an inverse correlation between PDEF and survivin expression and suggested that increased PDEF expression along with reduced survivin was associated with prolonged survival of patients with ovarian cancer.Keywords
This publication has 32 references indexed in Scilit:
- Cancer Statistics, 2007CA: A Cancer Journal for Clinicians, 2007
- The mechanism of methylselenocysteine and docetaxel synergistic activity in prostate cancer cellsMolecular Cancer Therapeutics, 2006
- Prostate-derived Ets transcription factor (PDEF) downregulates survivin expression and inhibits breast cancer cell growth in vitro and xenograft tumor formation in vivoBreast Cancer Research and Treatment, 2006
- Presalvage prostate‐specific antigen (PSA) and PSA doubling time as predictors of biochemical failure of salvage cryotherapy in patients with locally recurrent prostate cancer after radiotherapyCancer, 2006
- ETS transcription factors and their emerging roles in human cancerEuropean Journal Of Cancer, 2005
- Differential regulation of survivin expression and apoptosis by vitamin D3 compounds in two isogenic MCF-7 breast cancer cell sublinesOncogene, 2004
- Diverse Effects of Methylseleninic Acid on the Transcriptional Program of Human Prostate Cancer CellsMolecular Biology of the Cell, 2004
- Survivin study: What is the next wave?Journal of Cellular Physiology, 2003
- Tumor antigens and markers for breast and ovarian cancersFrontiers in Bioscience-Landmark, 2002
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958